Arlon Advisor

Arlon relies on Legorreta's long-duration relationships with food executives, commodity trading desks, and regional family-owned processors rather than auction processes. Because it deploys permanent balance-sheet capital without a fixed fund life, it often serves as the first institutional buyer for multigenerational dairy or protein companies in Latin America that would otherwise avoid private equity. The firm's operating partners embed directly into portfolio companies for multi-year post-acquisition periods to upgrade food-safety protocols and plant-level margins.

No. Arlon is capitalized exclusively by Pablo Legorreta and associated family entities. The firm has never disclosed any external fundraising and does not market itself as an alternative to institutional limited partners. This structure removes redemption pressures, quarterly reporting requirements, and fund-life constraints, allowing Arlon's food and agriculture holdings to be managed with a permanent-hold orientation.

Pablo Legorreta co-founded Royalty Pharma in 1996, building it into the dominant acquirer of pharmaceutical royalty streams before taking it public in 2020. Arlon Advisor was capitalized from his Royalty Pharma wealth but operates entirely separately — there is no shared investment team, no inter-firm credit facility, and no crossover between Royalty Pharma's healthcare-royalty portfolio and Arlon's food and agriculture holdings.

Arlon targets majority-control equity investments between $50 million and $300 million, executed as single-balance-sheet acquisitions without syndicated co-investors. It does not participate in minority-stake, growth-equity, or venture-stage food transactions. The firm's deals in dairy, meat and ingredient processing often involve primary production assets — ranches, slaughter facilities, and cold-storage plants — alongside the branded-product and distribution layers.

Arlon invests primarily across the Americas: the United States, Mexico, Brazil, and select Central and South American markets including Panama and Chile. Its portfolio includes US-based seafood importers and distributors as well as Latin American dairy, protein, and juice processors that serve both domestic consumption and export channels. The firm has not publicly announced investments in European or Asian food companies.